Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.
What is the present valuation and projected CAGR of the blood cancer drugs market?
The blood cancer drugs market size has grown strongly in recent years. It will grow from $74.78 billion in 2024 to $80.79 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to advancements in research and development, aging population, increased awareness and early diagnosis, regulatory approvals.
The blood cancer drugs market size is expected to see strong growth in the next few years. It will grow to $106.8 billion in 2029 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to increasing disease prevalence, emerging markets, supportive care. Major trends in the forecast period include research and development investments, combination therapies, biomarker identification, immunotherapy advancements, personalized medicine.
Get Your Free Sample of The Global Blood Cancer Drugs Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=2587&type=smp
What key drivers have fueled the blood cancer drugs market’s development over the years?
The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukemia, myeloma, and others have different risk factors some can be controlled or prevented through drug therapies and others may lead to death. For instance in November 2022, according to the Bristol-Myers Squibb Company report, over 1.85 million new blood cancer cases are expected to be diagnosed across the globe in 2040, out of which 918,872 cases are from lymphoma, 656,345 from leukemia, and 275,047 cases from myeloma. Furthermore, the report estimated, that in 2040, the approximate number of deaths worldwide due to blood cancer will be 1,100,000The increasing number of deaths and the increasing incidence of blood cancer cases globally drive the blood cancer drug market.
What is the segmentation for the blood cancer drugs market?
The blood cancer drugs market covered in this report is segmented –
1) By Blood Cancer Type: Leukemia, Lymphoma
2) By Drugs: Rituxan Or Mabthera (Rituximab), Gleevec Or Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin), Other Drugs
3) By Treatment Approaches: Key Findings, Chemotherapeutic, MAbs/Targeted Therapies, Immunotherapeutic
Subsegments:
1) By Leukemia: Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myeloid Leukemia (CML), Other Types of Leukemia
2) By Lymphoma: Hodgkin Lymphoma, Non-Hodgkin Lymphoma (NHL), Burkitt Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Other Types of Lymphoma
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report
Who are the most influential companies in the blood cancer drugs market?
Major companies operating in the blood cancer drugs market include Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Roche Holding AG, Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Chemicals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Chemicals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Regeneron Chemicals Inc., Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Chemicals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Chemicals Inc., UCB S.A., Vertex Chemicals Incorporated
What are the top industry trends projected to impact the blood cancer drugs market?
Major companies operating in the blood cancer drugs market are focusing on developing new drugs and pushing for FDA approval to gain a competitive edge in the market. FDA approval for drugs refers to the formal authorization granted by the United States Food and Drug Administration (FDA) for a pharmaceutical product to be legally marketed and sold in the United States. For instance, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical industry company, received FDA approval for its first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval allows its use in patients who have received at least two prior treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. Based on the TRANSCEND CLL 004 trial, Breyanzi demonstrated a 20% complete response rate and a median duration of response of 35.3 months among responders.
What are the major regional insights for the blood cancer drugs market, and which region holds the top position?
North America was the largest region in the blood cancer drugs market in 2023. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Does The Blood Cancer Drugs Market Report 2025 Offer?
The blood cancer drugs market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Blood Cancer Drugs Blood cancer drugs refer to the drugs or medications that are used to treat blood cancer drugs by using the body’s immune system to fight blood cancer by slowing down the growth of cancer cells. Chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplant are a few of the frequently used blood cancer treatments.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2587
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
